[18F]FDG accumulation in an experimental model of multistage progression of cholangiocarcinoma

Hepatology Research

Volumn 37, Issue 2, 2007, Pages 127-132

  Laverman, Peter ^a   Blokx, Willeke A M ^a   te Morsche, René H M ^a   Frielink, Cathelijne ^a   Boerman, Otto C ^a   Oyen, Wim J G ^a   Drenth, Joost P H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

18F FDG; Autoradiography; Carcinogenesis; Cholangiocarcinoma; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUTATHIONE TRANSFERASE; THIOACETAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BILE DUCT CARCINOMA; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG UPTAKE; EARLY DIAGNOSIS; ENZYME ACTIVITY; EXPERIMENTAL MODEL; HISTOCHEMISTRY; HISTOPATHOLOGY; HYPOTHESIS; LIVER CIRRHOSIS; LIVER PERFUSION; LIVER RESECTION; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT;

EID: 33947125679     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2007.00016.x     Document Type: Article

References (24)

1. Yalcin S. Diagnosis and management of cholangiocarcinomas: A comprehensive review. Hepatogastroenterology 2004; 51: 43-50.
2. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet 2005; 366: 1303-14.
3. Berthiaume EP, Wands J. The molecular pathogenesis of cholangiocarcinoma. Semin Liver Dis 2004; 24: 127-37.
4. Nehls O, Gregor M, Klump B. Serum and bile markers for cholangiocarcinoma. Semin Liver Dis 2004; 24: 139-54.
5. Yeh CN, Maitra A, Lee KF, Jan YY, Chen MF. Thioacetamide-induced intestinal-type cholangiocarcinoma in rat: An animal model recapitulating the multi-stage progression of human cholangiocarcinoma. Carcinogenesis 2004; 25: 631-6.
6. Drenth JP, Nagengast FM, Oyen WJ. Evaluation of (pre-) malignant colonic abnormalities: Endoscopic validation of FDG-PET findings. Eur J Nucl Med 2001; 28: 1766-9.
7. Jan YY, Yeh TS, Yeh JN, Yang HR, Chen MF. Expression of epidermal growth factor receptor, apomucins, matrix metalloproteinases, and p53 in rat and human cholangiocarcinoma: Appraisal of an animal model of cholangiocarcinoma. Ann Surg 2004; 240: 89-94.
8. Ruers TJ, Langenhoff BS, Neeleman N et al. Value of positron emission tomography with [F-18]fluorodeoxyglucose in patients with colorectal liver metastases: A prospective study. J Clin Oncol 2002; 20: 388-95.
9. Nakajima T, Takayama T, Miyanishi K et al. Reversal of Multiple Drug Resistance in Cholangiocarcinoma by the Glutathione S-Transferase-{pi}-Specific Inhibitor O1-Hexadecyl-{gamma}-glutamyl-S-benzylcysteinyl-D-phenylglycine Ethylester. J Pharmacol Exp Ther 2003; 306: 861-9.
10. Niu ZS, Wang M. Expression of c-erbB-2 and glutathione S-transferase-pi in hepatocellular carcinoma and its adjacent tissue. World J Gastroenterol 2005; 11: 4404-8.
11. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-75.
12. Peters WH, Te Morsche RH, Roelofs HM. Combined polymorphisms in UDP-glucuronosyltransferases 1A1 and 1A6: Implications for patients with Gilbert's syndrome. J Hepatol 2003; 38: 3-8.
13. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J Biol Chem 1974; 249: 7130-9.
14. Peters WH, Boon CE, Roelofs HM, Wobbes T, Nagengast FM, Kremers PG. Expression of drug-metabolizing enzymes and P-170 glycoprotein in colorectal carcinoma and normal mucosa. Gastroenterology 1992; 103: 448-55.
15. Al-Bader A, Mathew TC, Abul H, Al-Sayer H, Singal PK, Dashti HM. Cholangiocarcinoma and liver cirrhosis in relation to changes due to thioacetamide. Mol Cell Biochem 2000; 208: 1-10.
16. Morley CG, Boyer JL. Stimulation of hepatocellular proliferation by a serum factor from thioacetamide-treated rats. Biochim Biophys Acta 1977; 477: 165-76.
17. Schmidt KC, Smith CB. Resolution, sensitivity and precision with autoradiography and small animal positron emission tomography: implications for functional brain imaging in animal research. Nucl Med Biol 2005; 32: 719-25.
18. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998; 133: 510-15.
19. Fritscher-Ravens A, Bohuslavizki KH, Broering DC et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl Med Commun 2001; 22: 1277-85.
20. Keiding S, Hansen SB, Rasmussen HH et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998; 28: 700-6.
21. 18F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001; 33: 1029-35.
22. Anderson CD, Rice MH, Pinson CW, Chapman WC, Chari RS, Delbeke D. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004; 8: 90-7.
23. Kim YJ, Yun M, Lee WJ, Kim KS, Lee JD. Usefulness of 18 F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003; 30: 1467-72.
24. Fevery J, Buchel O, Nevens F, Verslype C, Stroobants S, Van Steenbergen SW. Positron emission tomography is not a reliable method for the early diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis. J Hepatol 2005; 43: 358-60.